On April 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater.
“Polatuzumab vedotin-piiq is an innovative treatment that offers a new option for patients, and another reason for this community to maintain hope for the future,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “New medicines can transform the way healthcare providers approach this type of blood cancer and we commend those who contribute to accelerating research for the benefit of patients, including those who participate in the clinical trials that lead to these approvals.”
For more information on the FDA approval of polatuzumab vedotin-piiq (Polivy), visit the FDA’s website. To learn more about treatment options for DLBCL, visit the DLBCL learning center.